---
title: "Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Clinical evidence"
description: "Formulary evidence on Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Clinical evidence. Covers INSPIRE, MT-7117-G01, ENDEAVOR, MT-7117-A-301, and MT-7117-E01. 109 evidence topics quoted from 27 sources."
canonical: "https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/clinical-evidence"
published: "2026-09-21T21:42:40-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 INSPIRE

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Primary objective

> “To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.”

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study status and dates

| Registry field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Start date, actual | “2023-12-11” |
| Primary completion, actual | “2026-04-14” |
| Completion, actual | “2026-05-19” |
| Enrollment, actual | “165” |

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="topic-3.1.1.2-2"></a>

###### Sponsor and geographic scope

> “The trial, mainly conducted by Tanabe Pharma America, Inc. (Jersey City, New Jersey, USA), enrolled 165 participants with EPP or XLP (aged 12 years and older and under 75 years).”

Source: [Tanabe Pharma Corporation INSPIRE topline results announcement (2026)](https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf)

<a id="topic-3.1.1.2-3"></a>

###### Posted results

No evidence found.

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomized, double-blind, placebo-controlled design with open-label extension

> “The INSPIRE study is a global, randomized, double-blind, placebo-controlled phase 3 clinical trial in adult and adolescent participants with EPP or XLP. Participants were randomly assigned to either a placebo group or an active treatment group (dersimelagon 200 mg once daily) for a 16-week double-blind period, followed by a 36-week open-label extension period of active treatment.”
> “The double-blind treatment phase has been completed, while the open-label phase is ongoing.”

Source: [Tanabe Pharma Corporation INSPIRE topline results announcement (2026)](https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf)

<a id="topic-3.1.1.3-2"></a>

###### Registry design fields

| Design field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Parallel” |
| Masking | “Quadruple” |
| Primary purpose | “treatment” |
| Phase | “Phase 3” |

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Diagnosis and age

> “Male and female subjects with a confirmed diagnosis of EPP or XLP based on medical history”
> “Subjects aged 12 years to 75 years, inclusive, at Screening”
> “In the Investigator's opinion, subject can understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements (including travel and receiving direct sunlight exposure as much as possible”

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="topic-3.1.1.4-2"></a>

###### Hepatic and dermatologic exclusions

> “Presence or history of any hepatobiliary disease, including druginduced liver injury at screening, determined as clinically significant by the Investigator after the discussion with the Sponsor Medical Monitor”
> “Subjects with aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≥ 2.0 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at Screening”
> “History of melanoma”

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="topic-3.1.1.4-3"></a>

###### Exclusion of prior dersimelagon and other investigational therapy

> “Subjects who participated in any previous MT-7117 clinical studies”
> “Previous treatment with any investigational agent such as bitopertin, within 12 weeks before Screening or 5 half-lives of the investigational product (whichever is longer”

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="topic-3.1.1.4-4"></a>

###### Erythrocyte protoporphyrin threshold for entry

No evidence found.

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Dose, route, and frequency

> “After screening, study participants (ranging from 12 to 75 years of age) received either dersimelagon 200 mg or placebo once daily.”

Source: [Tanabe Pharma America (2026)](https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-america-announces-positive-topline-results-for-dersimelagon-in-erythropoietic-protoporphyria-epp-and-x-linked-protoporphyria-xlp)

> “The study consists of a 16-week double-blind treatment period, in which participants are randomly assigned to either the placebo group or active treatment group (dersimelagon 200 mg once daily), followed by a 36-week open-label extension period of active treatment.”

Source: [Tanabe Pharma America (2026)](https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-america-announces-positive-topline-results-for-dersimelagon-in-erythropoietic-protoporphyria-epp-and-x-linked-protoporphyria-xlp)

<a id="topic-3.1.1.5-2"></a>

###### Restriction on zinc oxide sunscreen during treatment

> “Use of sunscreens with zinc oxide. Note: Sunscreens without zinc oxide are allowed, however their use, in frequency, quantity and body surface area should be maintained relatively stable throughout the duration of the study”

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Average Daily Sunlight Exposure Time to First Prodromal Symptom as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Registered definition of the primary outcome measure

> “Change from baseline in average daily sunlight exposure time (minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset at Week 16”
> “The comparison between MT-7117 treatment group and placebo group will be performed.”

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="topic-3.1.1.6.1-2"></a>

###### Registered secondary outcome measures

> “Patient Global Impression of Change (PGIC) at Week 16.”
> “Total number of sunlight-induced pain events defined as prodromal symptoms (burning, tingling, itching, or stinging) with pain rating of 1-10 on the Likert scale during the 16-week double-blind treatment period.”
> “Total number of sunlight-induced non-prodrome, phototoxic reactions during the 16-week double-blind treatment period.”

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)

<a id="topic-3.1.1.6.1-3"></a>

###### How participants were instructed to generate the endpoint

> “Because of how significant the phototoxic reactions are, we didn't want to ask patients to try to have a phototoxic reaction,”
> “But we did ask patients to try to have prodromal symptoms at least once weekly.”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.6.1-4"></a>

###### Regulatory precedent for sunlight-exposure time as a clinically meaningful endpoint

> “Accurately tracking sunlight exposure is important for evaluating new therapies and pain-free light exposure time is the precedented, clinically meaningful endpoint used to support afamelanotide's marketing authorization in the US and European Union.”

Source: [Mathias et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10660587/)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment

> “Up to 150 patients with a confirmed diagnosis of EPP or XLP from ages 12 to 75 years may qualify for enrollment.”

Source: [Tanabe Pharma America (2024)](https://us.tanabe-pharma.com/media/press-releases/2024/first-patient-enrolled-in-mtpa-inspire-study-of-investigational-dersimelagon-for-epp-and-xlp)

<a id="topic-3.1.1.7.1-2"></a>

###### Participants randomized per arm

> “Yeung and other global INSPIRE trial investigators enrolled 165 patients with EPP or XLP aged 12 years or older. They randomly assigned 82 patients to 200 mg dersimelagon daily and another 83 to placebo. Baseline characteristics were well balanced between groups. Double-blind assessment at week 16 was followed by a 36-week open-label extension.”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Balance of baseline characteristics between arms

> “Baseline characteristics were well balanced between groups.”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.8.2-2"></a>

###### Tabulated baseline characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint result

> “Dersimelagon, a selective agonist of melanocortin 1 receptor (MC1R), met the primary endpoint, showing a statistically significant prolongation of average daily sunlight exposure time to first prodromal symptom during Weeks 12–16 versus placebo, with a placebo-adjusted least-squares mean difference of 23.19 minutes (p=0.004) in primary analysis. At Week 16, the effect increased to 29.64 minutes (p=0.004) in supplementary analysis.”

Source: [Tanabe Pharma Corporation INSPIRE topline results announcement (2026)](https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### Result at the registered Week 16 timepoint

> “The primary endpoint was the change from baseline in average daily sunlight exposure time to first prodromal symptom at week 16. The time to prodrome was similar in both groups, Yeung said.”
> “During weeks 12-16, there was a statistically significant increase in the average daily time to first prodromal symptom, with a treatment difference of 23 minutes (P = .004).”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.8.3-3"></a>

###### Key secondary endpoint results

> “Key secondary endpoints were also met, including statistically significant differences in Patient Global Impression of Change (PGIC) and reduction of total pain events compared to placebo (PGIC: -1.83, p<0.001; reduction of total pain events: 39%, p=0.004), supporting clinical meaningful outcome of primary endpoint.”

Source: [Tanabe Pharma Corporation INSPIRE topline results announcement (2026)](https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf)

<a id="topic-3.1.1.8.3-4"></a>

###### Responder analyses reported at the congress presentation

> “a higher proportion of patients taking dersimelagon reported more than 33 minutes in time to prodrome (P = .04”
> “There also was an improvement in the proportion of patients experiencing more than 66 minutes outdoors without prodromal symptoms (P = .12).”
> “The study also met a secondary endpoint for the rate of sunlight-induced pain events, which was 39% lower with treatment than with placebo.”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.8.3-5"></a>

###### Phototoxic reactions occurring without a preceding prodrome

> “The investigators assessed the number of patients who skipped a prodrome and went directly to a full phototoxic reaction, “which is actually pretty rare in EPP,” she added. This outcome was underpowered and there was no statistically significant difference between groups.”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.8.3-6"></a>

###### Confidence intervals for the reported effect estimates

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Patient Global Impression of Change

> “A higher number of patients on dersimelagon reported “much better” and “moderately better” improvements in symptoms on the Patient Global Impression of Change (PGIC) tool. In the placebo group, patients typically reported “no change” or “a little bit better” symptoms, Yeung said. The difference in PGIC ratings was statistically significant between groups (P< .001).”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.8.4-2"></a>

###### Other patient-reported outcome instruments

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Overall tolerability and most common adverse events

> “The most common adverse events, occurring more frequently than placebo, were melanocytic nevi (benign moles), headache, nausea, diarrhea, and skin hyperpigmentation, with the mechanism of MC1R agonist.”
> “Dersimelagon was generally well-tolerated, with a safety profile consistent with its mechanism of action.”

Source: [Tanabe Pharma Corporation INSPIRE topline results announcement (2026)](https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf)

> “In the INSPIRE study, dersimelagon demonstrated a favorable safety and tolerability profile, with most adverse events being mild or moderate in severity.”

Source: [Tanabe Pharma America (2026)](https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-america-announces-positive-topline-results-for-dersimelagon-in-erythropoietic-protoporphyria-epp-and-x-linked-protoporphyria-xlp)

<a id="topic-3.1.1.8.5-2"></a>

###### Adverse event rates by treatment arm reported at the congress presentation

| Adverse event | Dersimelagon 200 mg | Placebo |
| --- | --- | --- |
| Headache | “22.0%” | “12.0%” |
| Melanocytic nevi | “20.7%” | “1.2%” |
| Nausea | “18.3%” | “10.8%” |

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.8.5-3"></a>

###### Serious adverse event of malignant melanoma in situ

> “Safety and tolerability “were quite good,” Yeung said. There were no deaths. There was one serious TEAE in the dersimelagon group — a patient who developed a malignant melanoma in situ. This person had a family history of malignant melanoma and had a lesion at the beginning of the study; the malignant melanoma in situ was identified on day 36.”
> “It was determined by the investigator to be related but determined by the sponsor to be unrelated,”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.8.5-4"></a>

###### Discontinuations

> “In the placebo group, TEAEs that led to discontinuation included brain fog and diarrhea.”
> “There was actually one discontinuation in the placebo group and one in the dersimelagon group for hyperpigmentation,”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

<a id="topic-3.1.1.8.5-5"></a>

###### Cumulative exposure in the development program

> “Dersimelagon has been studied in 410 participants with EPP or XLP to date”

Source: [Tanabe Pharma Corporation INSPIRE topline results announcement (2026)](https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: limitations of the INSPIRE evidence base

No results have been posted to ClinicalTrials.gov, the EU Clinical Trials Information System, or the Japan Registry of Clinical Trials, and no peer-reviewed publication exists. No protocol, statistical analysis plan, analysis-set definition, sample-size calculation, or multiplicity strategy is public, and no confidence interval has been published for any endpoint. Disposition, baseline characteristics, and complete adverse event tables are not available, and no results are reported separately for erythropoietic protoporphyria compared with X-linked protoporphyria or for the adolescent subgroup. The company reports the primary analysis over Weeks 12 to 16, whereas the registered primary outcome measure is at Week 16; the presenter reported that time to prodrome was similar between groups at Week 16 alone. Skin pigmentation is a pharmacologic effect of the drug, and in the phase 2 trial most participants correctly identified their assigned treatment, so blinding was incomplete. Participants were required to expose themselves to sunlight until symptoms developed, which may select for less severely affected individuals.

Source: [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840); [Tanabe Pharma Corporation INSPIRE topline results announcement (2026)](https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf); [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu); [Dechant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12751534/)

<a id="topic-3.1.1.9-2"></a>

###### Functional unblinding by treatment-induced pigmentation

> “Likewise, in the phase II trial investigating dersimelagon, 97% of the patients in the low dose group, 100% of the patients in the high dose group and 59% of the patients in the placebo group correctly guessed their treatment allocation”
> “During the approval procedures of afamelanotide, the EMA assessed that the lack of complete blinding of the trials impaired the validity of the evidence for efficacy, but also acknowledged that there was no possibility of blinding the studies appropriately”

Source: [Dechant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12751534/)

<a id="topic-3.1.1.9-3"></a>

###### Independent commentary on blinding and selection

> “It can be assumed that most patients in the INSPIRE trial did know to which treatment arm they had been randomized to, which might have influenced their sun exposure behavior,”
> “The melanocytic nevi rate was 20.7% in the dersimelagon group vs 1.2% in the placebo cohort. This difference “should be closely monitored,”

Source: [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)

Additional sources: [Barman-Aksözen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41885813/)

<a id="heading-3.1.2"></a>

#### 3.1.2 MT-7117-G01

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Primary objective

> “to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP”

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study status and dates

| Registry field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Start date, actual | “2020-06-01” |
| Primary completion, actual | “2021-12-14” |
| Completion, actual | “2022-07-26” |
| Enrollment, actual | “184” |

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

<a id="topic-3.1.2.2-2"></a>

###### Participants enrolled by country

> “Number of subjects enrolled per country Country: Number of subjects enrolled Norway: 3 Country: Number of subjects enrolled Spain: 11 Country: Number of subjects enrolled Sweden: 5 Country: Number of subjects enrolled United Kingdom: 14 Country: Number of subjects enrolled Germany: 6 Country: Number of subjects enrolled Italy: 21 Country: Number of subjects enrolled United States: 93 Country: Number of subjects enrolled Japan: 11 Country: Number of subjects enrolled Australia: 12 Country: Number of subjects enrolled Canada: 8 Worldwide total number of subjects 184 EEA total number of subjects 46”
> “Global end of trial date 26 Jul 2022”

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Registry design fields

| Design field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Parallel” |
| Masking | “Triple” |
| Primary purpose | “treatment” |
| Phase | “Phase 3” |

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Age, diagnosis, and body weight

> “Male and female subjects with a confirmed diagnosis of EPP or XLP based on medical history, aged 12 years to 75 years, inclusive, at Screening”
> “Subjects have a body weight of ≥30 kg”

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

<a id="topic-3.1.2.4-2"></a>

###### Hepatic, dermatologic, and renal exclusions

> “History or presence of photodermatoses other than EPP or XLP”
> “Subjects with AST, ALT, ALP ≥3.0 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at Screening”
> “History of melanoma”
> “History of familial melanoma (defined as having 2 or more first-degree relatives, such as parents, sibling and/or child”

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

<a id="topic-3.1.2.4-3"></a>

###### Prohibited prior and concomitant therapy

> “Treatment with phototherapy within 3 months before Randomization (Visit 2”
> “Treatment with afamelanotide within 3 months before Randomization (Visit 2”
> “Treatment with antioxidant agents within 4 weeks before Randomization (Visit 2), at doses which, in the opinion of the Investigator, may affect study endpoints (including but not limited to beta-carotene, cysteine, pyridoxine”

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Registry arm descriptions

> “Oral tablet of placebo once a day.”
> “Oral tablet of MT-7117 Low Dose once a day.”
> “Oral tablet of MT-7117 High Dose once a day.”

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

<a id="topic-3.1.2.5-2"></a>

###### Tablet strength and number of tablets per arm

> “Arm title MT-7117 low dose”
> “Dosage and administration details Subjects self-administered 2 tablets of investigational medicinal product (IMP) with or without food each morning. Subjects received 1 tablet of MT-7117 and 1 tablet of matching placebo”

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.5-3"></a>

###### Disclosed dose amounts

No evidence found.

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Average Daily Sunlight Exposure Time to First Prodromal Symptom as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Definition of the primary efficacy endpoint and its averaging window

> “Change from baseline in average daily sunlight exposure time (minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset at Week 26 (Visit 7”

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.6.1-2"></a>

###### Secondary efficacy endpoints

> “Patient Global Impression of Change (PGIC) at Week 26”
> “The percentage of subjects who are responders based on average daily sunlight exposure time to first prodromal symptom associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset defined by within-subject meaningful change of 66 minutes increase from baseline to Week 26”

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Participants analyzed by population

| Population | Placebo | MT-7117 low dose | MT-7117 high dose |
| --- | --- | --- | --- |
| Randomized and started double-blind treatment | “61” | “63” | “60” |
| Primary endpoint analysis set | “60” | “63” | “60” |
| PROMIS-57 analyses | “49” | “59” | “56” |
| Patient Global Impression of Change analysis | “56” | “59” | “56” |

Source: [ClinicalTrials.gov NCT04402489 results](https://clinicaltrials.gov/study/NCT04402489?tab=results)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Definition of the efficacy analysis set

> “Included all randomized subjects who received at least 1 dose of study medication with Baseline and post randomization- sunlight exposure diary assessments during the double-blind treatment period”

Source: [ClinicalTrials.gov NCT04402489 results](https://clinicaltrials.gov/study/NCT04402489?tab=results)

<a id="topic-3.1.2.7.2-2"></a>

###### Point at which sequential testing stopped

> “Because MT-7117 High Dose did not demonstrate statistically significant differences compared to placebo, the prespecified sequential testing was stopped before formally statistically testing the next hypothesis of the primary endpoint of Low Dose and the secondary endpoints. Therefore, Nominal p values presented for these endpoints are for descriptive purposes only. Consequently, the subsequent primary endpoint of the MT-7117 Low Dose group and the secondary endpoints were not formally tested.”

Source: [jRCT2080225355](https://jrct.mhlw.go.jp/latest-detail/jRCT2080225355)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Disposition during the 26-week double-blind treatment period

| Disposition | Placebo | MT-7117 low dose | MT-7117 high dose |
| --- | --- | --- | --- |
| Started | “61” | “63” | “60” |
| Completed | “57” | “60” | “58” |
| Not completed | “4” | “3” | “2” |
| Adverse event | “0” | “1” | “0” |
| Physician decision | “1” | “0” | “0” |
| Withdrawal by subject | “3” | “2” | “2” |

Source: [ClinicalTrials.gov NCT04402489 results](https://clinicaltrials.gov/study/NCT04402489?tab=results)

<a id="topic-3.1.2.8.1-2"></a>

###### Entry into the double-blind extension

> “Of 57 participants randomized to placebo in 26 weeks double-blind period, 28 were re-randomized to MT-7117 low dose, and 28 were re-randomized to MT-7117 high dose”

Source: [ClinicalTrials.gov NCT04402489 results](https://clinicaltrials.gov/study/NCT04402489?tab=results)

<a id="topic-3.1.2.8.1-3"></a>

###### Number screened and screen failures

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Age distribution and sex

| Characteristic | Placebo | MT-7117 low dose | MT-7117 high dose | Total |
| --- | --- | --- | --- | --- |
| Adolescents aged 12 to 17 years | “12” | “13” | “12” | “37” |
| Adults aged 18 to 65 years | “47” | “45” | “46” | “138” |
| Older than 65 years | “2” | “5” | “2” | “9” |
| Age in years, arithmetic mean (standard deviation) | “34.1 ( 15.6” | “33.5 ( 17.1” | “34.4 ( 15.3” | “184” |
| Female | “30” | “30” | “33” | “93” |
| Male | “31” | “33” | “27” | “91” |

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.8.2-2"></a>

###### Race and ethnicity

| Category | Placebo | MT-7117 low dose | MT-7117 high dose |
| --- | --- | --- | --- |
| Hispanic or Latino | “7” | “7” | “2” |
| Not Hispanic or Latino | “53” | “52” | “58” |
| White | “52” | “60” | “55” |
| Asian | “9” | “1” | “2” |
| Black or African American | “0” | “0” | “0” |

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.8.2-3"></a>

###### Baseline disease characteristics, including diagnosis split and protoporphyrin concentrations

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary endpoint: change from baseline in average daily sunlight exposure time to first prodromal symptom at Week 26

| Arm | Least-squares mean change, minutes | Standard error |
| --- | --- | --- |
| Placebo | “20.59” | “10.29” |
| MT-7117 low dose | “30.39” | “10.04” |
| MT-7117 high dose | “43.29” | “10.13” |

Source: [ClinicalTrials.gov NCT04402489 results](https://clinicaltrials.gov/study/NCT04402489?tab=results)

| Comparison with placebo | Least-squares mean difference, minutes | 95% confidence interval | P value |
| --- | --- | --- | --- |
| MT-7117 low dose | “9.8” | “-18.52” to “38.12” | “0.496” |
| MT-7117 high dose | “22.7” | “-5.68” to “51.09” | “0.116” |

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.8.3-2"></a>

###### Sponsor description of the primary endpoint outcome

> “For the primary efficacy endpoint, change from baseline in average daily sunlight exposure time (minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset at Week 26 (Visit 7), MT-7117 High Dose did not demonstrate statistically significant improvement over placebo (LSMD = 22.70 minutes, p = 0.116).”

Source: [jRCT2080225355](https://jrct.mhlw.go.jp/latest-detail/jRCT2080225355)

<a id="topic-3.1.2.8.3-3"></a>

###### Secondary endpoint: Patient Global Impression of Change at Week 26

| Arm | Least-squares mean, points | Least-squares mean difference from placebo | 95% confidence interval | Nominal P value |
| --- | --- | --- | --- | --- |
| Placebo | “3.25” | | | |
| MT-7117 low dose | “2.41” | “-0.84” | “-1.23” to “-0.44” | “< 0.001” |
| MT-7117 high dose | “1.82” | “-1.43” | “-1.83” to “-1.03” | “< 0.001” |

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.8.3-4"></a>

###### Secondary endpoint: total number of sunlight-induced pain events over 26 weeks

| Arm | Geometric mean number of events | Incident rate ratio compared with placebo | 95% confidence interval | Nominal P value |
| --- | --- | --- | --- | --- |
| Placebo | “23.9” | | | |
| MT-7117 low dose | “15.87” | “0.76” | “0.49” to “1.16” | “0.199” |
| MT-7117 high dose | “13.78” | “0.55” | “0.36” to “0.84” | “0.006” |

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.8.3-5"></a>

###### Secondary endpoint: responder rate using the 66-minute within-subject meaningful change

| Arm | Responders, percentage of participants | Odds ratio compared with placebo | 95% confidence interval | Nominal P value |
| --- | --- | --- | --- | --- |
| Placebo | “12” | | | |
| MT-7117 low dose | “11” | “0.805” | “0.323” to “2.007” | “0.642” |
| MT-7117 high dose | “16” | “1.412” | “0.598” to “3.336” | “0.431” |

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.8.3-6"></a>

###### Independent characterization of the trial outcome

> “The first published phase II trial results demonstrated effectiveness,”
> “while the phase III trial did not meet its primary efficacy endpoint”

Source: [Minder et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11669082/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### PROMIS-57 pain intensity domain, change from baseline at Week 26

| Arm | Least-squares mean change | Least-squares mean difference from placebo | 95% confidence interval | Nominal P value |
| --- | --- | --- | --- | --- |
| Placebo | “-1.42” | | | |
| MT-7117 low dose | “-1.56” | “-0.15” | “-0.62” to “0.33” | “0.55” |
| MT-7117 high dose | “-1.65” | “-0.23” | “-0.72” to “0.25” | “0.343” |

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.8.4-2"></a>

###### PROMIS-57 physical function domain, change from baseline at Week 26

| Arm | Least-squares mean change | Least-squares mean difference from placebo | 95% confidence interval | Nominal P value |
| --- | --- | --- | --- | --- |
| Placebo | “0.67” | | | |
| MT-7117 low dose | “1.54” | “0.87” | “-0.08” to “1.82” | “0.072” |
| MT-7117 high dose | “1.22” | “0.56” | “-0.4” to “1.51” | “0.252” |

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Deaths and serious adverse events by period and arm

| Group | Deaths, affected of at risk | Serious adverse events, affected of at risk |
| --- | --- | --- |
| Double-blind treatment, placebo | “0” | “0” |
| Double-blind treatment, MT-7117 low dose | “0” | “2” |
| Double-blind treatment, MT-7117 high dose | “1” | “2” |
| Double-blind extension, placebo to low dose | “0” | “2” |
| Double-blind extension, placebo to high dose | “0” | “1” |
| Double-blind extension, MT-7117 low dose | “0” | “1” |
| Double-blind extension, MT-7117 high dose | “0” | “2” |

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

<a id="topic-3.1.2.8.5-2"></a>

###### Non-serious adverse events reported at the 5% threshold during double-blind treatment

| MedDRA preferred term | Placebo | MT-7117 low dose | MT-7117 high dose |
| --- | --- | --- | --- |
| Nausea | “4” | “4” | “17” |
| Headache | “3” | “8” | “9” |
| Diarrhoea | “1” | “5” | “8” |
| Melanocytic naevus | “1” | “6” | “8” |
| Skin hyperpigmentation | “1” | “3” | “8” |
| Skin discolouration | “0” | “5” | “6” |
| Ephelides | “1” | “3” | “4” |
| Photosensitivity reaction | “6” | “1” | “2” |
| Porphyria non-acute | “5” | “1” | “1” |
| Alanine aminotransferase increased | “1” | “3” | “0” |
| Aspartate aminotransferase increased | “1” | “4” | “0” |
| Gamma-glutamyltransferase increased | “5” | “3” | “1” |

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)

<a id="topic-3.1.2.8.5-3"></a>

###### Overall burden of non-serious adverse events

> “Total subjects affected by non serious adverse events subjects affected / exposed 40 / 61 (65.57%) 44 / 63 (69.84%) 44 / 60 (73.33”

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.8.5-4"></a>

###### Serious adverse events by term

> “There were 4 subjects (3.3%) who experienced serious TEAEs, 2 subjects in the MT-7117 Low Dose group, 2 subjects in the MT-7117 High Dose group, and no subjects in the placebo group. In the MT-7117 Low Dose group, 1 subject experienced myocarditis, and 1 subject experienced meningitis viral. In the MT-7117 High Dose group, 1 subject experienced asthma that was considered moderate. One subject in the MT-7117 High Dose group experienced a severe event of cholestasis with a fatal outcome.”
> “Six subjects (3.6%) experienced serious TEAEs in the MT-7117 combined group: hepatic enzyme increased (2 [7.1%]) placebo to MT-7117 Low Dose; porphyria non acute (1 [3.6%]) placebo to MT-7117 High Dose; pericarditis (1 [1.8%]) MT-7117 Low Dose; esophagitis (1 [1.9%]) and fibula fracture (1 [1.9%]) in MT-7117 High Dose.”

Source: [jRCT2080225355](https://jrct.mhlw.go.jp/latest-detail/jRCT2080225355)

<a id="topic-3.1.2.8.5-5"></a>

###### Independent safety oversight

> “An external independent Data Monitoring Committee was established to perform regular review of safety data to ensure the ongoing safety of participating subjects until the last subject completed the Double blind extension period.”

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf); [Mitsubishi Tanabe Pharma Development America (2022)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/SAP_001.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: interpretation of the first phase 3 trial

The trial did not meet its primary endpoint at either dose. Type I error was controlled by a fixed-sequence procedure in which the high dose was tested first; because that comparison was not statistically significant, testing stopped, and every subsequent P value, including those for the low dose, the Patient Global Impression of Change, and the pain-event count, is nominal and descriptive rather than confirmatory. The pre-specified 66-minute responder analysis was negative at both doses, and the placebo group improved by 20.59 minutes, a change of similar magnitude to the treatment differences observed. The sample size was calculated to detect a treatment difference of 52 to 57 minutes, and the observed differences were 9.8 minutes at the low dose and 22.7 minutes at the high dose. One death occurred, from cholestasis in the high-dose arm, the only death reported anywhere in the dersimelagon program in these disorders; the investigator assessed it as probably related to study drug and the sponsor as unlikely or unrelated, and an institutional review board suspended dosing at United States sites from July 14 to July 20, 2021. Two further serious hepatic enzyme elevations occurred in participants switching from placebo to active drug in the extension period. The actual dose amounts are redacted in every public document, no peer-reviewed publication exists, and no baseline disease characteristics, diagnosis subgroup, adolescent subgroup, or exploratory endpoint results have been posted. The sponsor reported no limitations in its results summary.

Source: [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489); [jRCT2080225355](https://jrct.mhlw.go.jp/latest-detail/jRCT2080225355); [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf); [Mitsubishi Tanabe Pharma Development America (2022)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/SAP_001.pdf); [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.9-2"></a>

###### Limitations declared by the sponsor

> “Limitations and caveats”
> “None reported”

Source: [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)

<a id="topic-3.1.2.9-3"></a>

###### Independent critique of the prodromal-symptom endpoint

> “The trials investigating dersimelagon use “time to prodrome” as their primary efficacy outcome measure. Prodromal symptoms are a newly introduced concept of early warning signals for a phototoxic reaction such as itching, tingling, burning and stinging.”
> “However, in their study, 76% of the participants reported having recovery times of one up to five days after experiencing a prodrome, and 46% experienced pain despite immediately exiting the sun.”
> “Consistent with our assessment, phototoxic pain events were observed in all treatment arms in the phase II trial investigating dersimelagon, i.e., in the placebo, low dose and high dose treatment groups [ 52 ]. Therefore, the endpoint “time to prodrome” does not prevent participants from developing severe reactions.”

Source: [Dechant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12751534/)

<a id="heading-3.1.3"></a>

#### 3.1.3 ENDEAVOR

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Purpose of the study

> “The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight exposure duration without symptoms and tolerance in subjects with EPP.”

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)

<a id="topic-3.1.3.1-2"></a>

###### Trial name and registration

> “(Funded by Mitsubishi Tanabe Pharma; Endeavor ClinicalTrials.gov number, NCT03520036.).”

Source: [Balwani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37043653/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study status and dates

| Registry field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Start date, actual | “2018-07-05” |
| Primary completion, actual | “2019-09-28” |
| Completion, actual | “2019-09-28” |
| Enrollment, actual | “102” |

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Period structure and total participation

> “This is a Phase 2, randomized, double-blind, placebo controlled study to assess the efficacy, tolerability, and safety of MT-7117 in subjects with EPP. The study consists of a 2 week screening period, a 16 week double-blind treatment period, and a 6 week follow-up period at Week 22. The total participation period is approximately 24 weeks.”

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)

<a id="topic-3.1.3.3-2"></a>

###### Absence of an open-label extension

No evidence found.

Additional sources: [Mitsubishi Tanabe Pharma Development America (2019)](https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/Prot_000.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Age and diagnosis

> “2. Male and female subjects with a confirmed diagnosis of EPP based on medical history, aged 18 years to 75 years, inclusive, at Screening.”

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)

<a id="topic-3.1.3.4-2"></a>

###### Hepatic, dermatologic, and renal exclusions

> “3. Presence of clinically significant hepatobiliary disease based on LFT values at Screening.”
> “4. Subjects with AST, ALT, ALP ≥3.0 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at Screening.”
> “6. History or presence of melanoma and/or atypical nevus at Screening.”
> “7. History of familial melanoma (defined as having 2 or more first-degree relatives, such as parents, sibling and/or child).”

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)

<a id="topic-3.1.3.4-3"></a>

###### Prohibited prior and concomitant therapy

> “15. Treatment with afamelanotide within 3 months before Randomization (Visit 2).”
> “18. Chronic treatment with prescription-based analgesic agents including but not limited to opioids and opioid derivatives such as morphine, hydrocodone, oxycodone or their combination with other analgesics or non-steroidal anti-inflammatory drug (NSAID, as Percocet and Vicodin-like prescription drugs) within 4 weeks before Randomization (Visit 2).”
> “20. Previous exposure to MT 7117.”

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Doses studied

> “Patients 18 to 75 years of age were randomly assigned in a 1:1:1 ratio to receive placebo or dersimelagon at a dose of 100 or 300 mg once daily for 16 weeks.”

Source: [Balwani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37043653/)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2019)](https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/Prot_000.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Average Daily Time to First Prodromal Symptom as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Clinical rationale for a prodromal-symptom endpoint

> “Before the onset of phototoxic pain, patients experience characteristic prodromal symptoms which serves as a warning signal to avoid further sun exposure. Of note, patients with higher ePPIX levels report shorter times to symptoms compared to patients with lower median ePPIX levels (JAMA Derm, 2017; 153).”

Source: [Balwani et al. (2020)](https://ash.confex.com/ash/2020/webprogram/Paper142467.html)

<a id="topic-3.1.3.6.1-2"></a>

###### Pharmacodynamic outcome measure

> “Pigmentation will be assessed in melanin density which are numeric scores measured by spectrophotometer on 6 skin segments (forehead, left cheek, right inside upper arm, left medial forearm, right-hand side of abdomen, and left-hand side of buttock).”

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2019)](https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/Prot_000.pdf)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Participants randomized

> “Of the 102 patients (93 with erythropoietic protoporphyria and 9 with X-linked protoporphyria) who underwent randomization, 90% completed the treatment period.”

Source: [Balwani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37043653/)

> “A total of 102 EPP/XLP patients were randomized to 3 groups: placebo once daily (QD) (n=35 [31 EPP/4 XLP]), MT-7117 100 mg QD (n=33 [31 EPP/2 XLP]), and MT-7117 300 mg QD (n=34 [31 EPP/3 XLP]).”

Source: [Balwani et al. (2020)](https://ash.confex.com/ash/2020/webprogram/Paper142467.html)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2019)](https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/Prot_000.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

Additional sources: [Mitsubishi Tanabe Pharma Development America (2019)](https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/Prot_000.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Disposition over the whole study

| Disposition | MT-7117 low dose | MT-7117 high dose | Placebo |
| --- | --- | --- | --- |
| Started | “33” | “34” | “35” |
| Completed | “31” | “30” | “31” |
| Not completed | “2” | “4” | “4” |
| Withdrawn for an adverse event | “1” | “2” | “0” |
| Withdrawn for a protocol violation | “1” | “0” | “0” |
| Withdrawn by subject | “0” | “1” | “4” |

Source: [ClinicalTrials.gov NCT03520036 results](https://clinicaltrials.gov/study/NCT03520036?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

###### Dosing error affecting the safety population

> “One subject who was randomized to Placebo received MT-7117 high Dose instead of placebo. Therefore, the subject was counted as MT-7117 high Dose Group in the Safety Population”

Source: [ClinicalTrials.gov NCT03520036 results](https://clinicaltrials.gov/study/NCT03520036?tab=results)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographics of the randomized population

| Characteristic | MT-7117 low dose | MT-7117 high dose | Placebo | Total |
| --- | --- | --- | --- | --- |
| Age in years, mean | “41.8” | “41.9” | “38.1” | “40.6” |
| Age in years, standard deviation | “12.8” | “14” | “12.6” | “13.1” |
| Female | “15” | “25” | “13” | “53” |
| Male | “18” | “9” | “22” | “49” |
| White | “33” | “33” | “32” | “98” |
| Asian | “0” | “0” | “1” | “1” |
| Black or African American | “0” | “0” | “0” | “0” |

Source: [ClinicalTrials.gov NCT03520036 results](https://clinicaltrials.gov/study/NCT03520036?tab=results)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary endpoint result

> “The mean daily time to the first prodromal symptom associated with sunlight exposure increased significantly with dersimelagon: the least-squares mean difference from placebo in the change from baseline to week 16 was 53.8 minutes in the 100-mg dersimelagon group (P = 0.008) and 62.5 minutes in the 300-mg dersimelagon group (P = 0.003).”

Source: [Balwani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37043653/)

<a id="topic-3.1.3.8.3-2"></a>

###### Unadjusted change from baseline by arm

| Outcome measure, change from baseline to Week 16, minutes | MT-7117 low dose | MT-7117 high dose | Placebo |
| --- | --- | --- | --- |
| Average daily time to first prodromal symptom, mean | “74.7” | “92.4” | “21.0” |
| Average daily time to first prodromal symptom, standard deviation | “76.8” | “100” | “63.4” |
| Average daily duration of sunlight exposure without prodromal symptoms, mean | “72.6” | “86.1” | “19.9” |

Source: [ClinicalTrials.gov NCT03520036 results](https://clinicaltrials.gov/study/NCT03520036?tab=results)

<a id="topic-3.1.3.8.3-3"></a>

###### Secondary endpoint results

> “There was a significant increase in average daily minutes of sunlight exposure without prodromal symptoms at Week 16 in 100 mg (p=0.009) and 300 mg (p=0.004) treated subjects compared to placebo, with an increased average exposure time without prodromal symptoms of ~50 min in MT-7117 subjects at both doses compared to placebo. There was also a 40% reduction in the total number of sunlight exposure episodes with prodromal symptoms in 100 mg (p=0.019) and 300 mg (p=0.006) subjects compared to placebo. There was a significant decrease in the total number of pain events reported in 100 mg (p=0.027, 60% reduction) and 300 mg (p=0.028, 50% reduction) subjects compared to placebo.”

Source: [Balwani et al. (2020)](https://ash.confex.com/ash/2020/webprogram/Paper142467.html)

<a id="topic-3.1.3.8.3-4"></a>

###### Consistency of effect across seasons and geographic regions

> “Results: TTP at baseline was similar across seasons, and both subgroups observed an increase in TTP at week 16. This increase was statistically significant for subgroup 2 (LSMD [SE] = 48.4 [21.9], P = .032 for 100 mg dersimelagon and LSMD [SE] = 66.0 [22.1], P = .004 for 300 mg dersimelagon vs placebo).”
> “Conclusions: This post hoc analysis demonstrates that improvement in average daily TTP after treatment with dersimelagon is maintained regardless of season and geographic region in individuals with EPP.”

Source: [Belongie et al. (2022)](https://www.jaad.org/article/S0190-9622(22)01702-9/fulltext)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Quality of life reported in the primary publication

> “The results also suggest that quality of life improved in patients receiving dersimelagon as compared with placebo.”

Source: [Balwani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37043653/)

<a id="topic-3.1.3.8.4-2"></a>

###### Exit questionnaire responses

> “Additionally, an online questionnaire assessing quality of life was completed by 75 of the 102 patients enrolled. Of those taking dersimelagon 100 mg, 57.6% rated their EPP as “very much better” and 69.7% rated they were “much more often” able to be outside at the end of the study. Likewise, among those who used dersimelagon 300 mg, positive ratings were given by 48.6%.”

Source: [Madigan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10819203/)

<a id="topic-3.1.3.8.4-3"></a>

###### Posted PROMIS-57 and Patient Global Impression of Change results

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Most common adverse events

> “The most common adverse events that occurred or worsened during treatment were nausea, freckles, headache, and skin hyperpigmentation.”

Source: [Balwani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37043653/)

> “MT-7117 had an acceptable safety and tolerability profile. The most common treatment-related treatment emergent adverse reactions were nausea (27.9%), ephelides (23.5%), and skin hyperpigmentation (20.6%).”

Source: [Balwani et al. (2020)](https://ash.confex.com/ash/2020/webprogram/Paper142467.html)

<a id="topic-3.1.3.8.5-2"></a>

###### Deaths and serious adverse events

| Safety summary | MT-7117 low dose | MT-7117 high dose | Placebo |
| --- | --- | --- | --- |
| Deaths | “0” | “0” | “0” |
| Serious adverse events | “1” | “0” | “0” |
| Other non-serious adverse events | “31” | “34” | “31” |

Source: [ClinicalTrials.gov NCT03520036 results](https://clinicaltrials.gov/study/NCT03520036?tab=results)

<a id="topic-3.1.3.8.5-3"></a>

###### Non-serious adverse events reported at the 3% threshold

| MedDRA preferred term | MT-7117 low dose | MT-7117 high dose | Placebo |
| --- | --- | --- | --- |
| Nausea | “5” | “16” | “4” |
| Ephelides | “5” | “11” | “0” |
| Skin hyperpigmentation | “3” | “11” | “0” |
| Headache | “6” | “10” | “6” |
| Diarrhoea | “4” | “8” | “4” |
| Melanocytic naevus | “4” | “7” | “3” |
| Fatigue | “1” | “6” | “1” |
| Photosensitivity reaction | “5” | “5” | “3” |
| Skin discolouration | “1” | “3” | “0” |
| Urticaria | “0” | “2” | “0” |
| Hepatic enzyme increased | “1” | “0” | “0” |
| Anaphylactic reaction | “1” | “0” | “0” |

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)

<a id="topic-3.1.3.8.5-4"></a>

###### Discontinuations and the serious adverse event causality assessment

> “Participation in the trial was discontinued by four patients in the placebo group (voluntary withdrawal), two patients in the 100 mg dersimelagon group (one for nonadherence and one for a serious adverse event), and four patients in the 300 mg dersimelagon group (one voluntary withdrawal, two withdrawals for adverse events, and one withdrawal for clinically significant lichen planus found during nevi assessment). The serious adverse event that led to discontinuation by one patient in the 100 mg dersimelagon group was an anaphylactic reaction that was deemed by the investigators to be unrelated to dersimelagon”

Source: [Madigan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10819203/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: limitations of the phase 2 trial

The trial enrolled adults only, was conducted entirely in the United States, and 98 of 102 participants were White with no Black participants. There was no formal power calculation and no multiplicity adjustment across three registered primary outcome measures and seven secondary endpoints, and the registry posts no confidence intervals or P values for any outcome. Sex was unevenly distributed, with 25 of 34 participants female in the high-dose arm compared with 13 of 35 in the placebo arm. Blinding was incomplete because the drug increases skin pigmentation. The erythrocyte protoporphyrin and seasonal subgroup analyses were post hoc. The larger phase 3 trial that followed, using the same primary endpoint at Week 26, did not reproduce the effect size observed here.

Source: [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036); [Mitsubishi Tanabe Pharma Development America (2019)](https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/Prot_000.pdf); [Madigan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10819203/); [Balwani et al. (2020)](https://ash.confex.com/ash/2020/webprogram/Paper142467.html)

<a id="topic-3.1.3.9-2"></a>

###### Incomplete blinding and absence of a power analysis

> “Additionally, there was incomplete blinding in this trial due to increases in skin pigmentation when taking dersimelagon, which allowed many subjects to correctly guess if they were assigned to the active drug group.”
> “In the phase 2 trial, limitations included a lack of formal statistical power analysis, although such limitations are common in studies of rare diseases such as EPP/XLP”

Source: [Madigan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10819203/)

<a id="topic-3.1.3.9-3"></a>

###### Critique of the prodromal-symptom endpoint and of placebo control

> “Recognizing the seriously harmful consequences of daylight exposure for EPP patients, investigators in the dersimelagon trial specified endpoints in terms of minutes of exposure before the appearance of prodromal symptoms.”
> “Further, the tingling and itching is not always present. At times, the phototoxic reaction directly starts with the pain, or with a combination of milder symptoms and pain.”
> “Further, being melanocortin receptor agonists, afamelanotide and dersimelagon both increase skin pigmentation and cause partial unblinding of the trial participants in the active treatment group – thus undermining the rationale for the use of placebo controls.”

Source: [Barman-Aksözen et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10580501/)

<a id="heading-3.1.4"></a>

#### 3.1.4 MT-7117-A-301

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Primary objective

> “To evaluate the long-term safety and tolerability of oral dersimelagon.”

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study title, status, and dates

| Registry field | Quoted record |
| --- | --- |
| Official title | “A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)” |
| Overall status | “Active, not recruiting” |
| Start date, actual | “2021-08-10” |
| Primary completion, estimated | “2027-12” |
| Enrollment, actual | “286” |

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Open-label single-group design

| Design field | Quoted record |
| --- | --- |
| Allocation | “na” |
| Intervention model | “Single group” |
| Masking | “None” |
| Phase | “Phase 3” |

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)

<a id="topic-3.1.4.3-2"></a>

###### Relationship to the other trials in the program

> “Another open-label extension study will continue to evaluate the long-term safety and tolerability of dersimelagon and enroll participants from the INSPIRE study and participants who have completed the study MT-7117-G01, if interested.”

Source: [Tanabe Pharma America (2025)](https://us.tanabe-pharma.com/news-and-media/press-releases/2025/mitsubishi-tanabe-pharma-america-announces-completion-of-enrollment-for-its-phase-3-inspire-study-of-investigational-dersimelagon-in-patients-with-epp-and-xlp)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Rollover eligibility from the phase 3 trials

> “2. Subjects who have completed: MT-7117-G01 (completed through Week 58 [Visit 12]) or, MT-7117-A-302 (completed through Week 58 [Visit 10]) or, MT-7117-A-301 (completed EOT - Week 104 or Week 130) according to protocol amendment 1 or 2.”

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)

<a id="topic-3.1.4.4-2"></a>

###### Hepatic and dermatologic exclusions

> “3. Subjects with AST, ALT, ALP ≥ 3.0 × upper limit of normal (ULN) or TB > 1.5 × ULN at Screening. The TB level of > 1.5 × ULN listed in this exclusion criteria may not be applicable to subjects with a documented medical history of Gilbert's syndrome.”
> “5. History of melanoma.”

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dose and route

> “Dersimelagon 200mg”

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Safety outcome measures and observation period

> “Number of patients with Treatment emergent adverse events (TEAEs) (including serious adverse events [SAEs] and adverse events of special interest [AESIs]).”
> “Number of patients with Nevi appearance”
> “up to 66 further months”

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)

<a id="topic-3.1.4.6.1-2"></a>

###### Absence of efficacy endpoints

> “E.6.4 Safety Yes E.6.5 Efficacy No”

Source: [EU Clinical Trials Register (2021)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001831-17/IT/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Participants enrolled

| Registry field | Quoted record |
| --- | --- |
| Enrollment, actual | “286” |

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: status of the long-term extension

The study is open-label and single-group, so it provides no controlled comparison. It remains ongoing with estimated completion in December 2027, and no results have been posted to ClinicalTrials.gov or the EU Clinical Trials Register. Enrollment is restricted to participants who completed one of the two phase 3 trials or a previous period of the extension itself, which excludes participants from the phase 2 trial and selects for people who tolerated and continued earlier treatment.

Source: [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975); [EU Clinical Trials Register (2021)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001831-17/IT/)

<a id="heading-3.1.5"></a>

#### 3.1.5 MT-7117-E01

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Purpose of the first-in-human study

> “In this double-blind, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of dersimelagon in healthy participants were evaluated.”

Source: [Ogasawara et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10229459/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

No evidence found.

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Single and multiple ascending dose design

> “In this double-blind, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of dersimelagon in healthy participants were evaluated.”

Source: [Ogasawara et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10229459/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Doses administered

> “No treatment-related effects on melanin density (MD) were observed following single doses of dersimelagon; however, after multiple doses, increases in MD were observed in participants receiving 150 and 300 mg dersimelagon.”

Source: [Ogasawara et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10229459/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Melanin Density as a Pharmacodynamic Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Melanin density as the pharmacodynamic measure of target engagement

> “Treatment-related increases in MD warrant further investigation in a larger study population and in patients with EPP and XLP.”

Source: [Ogasawara et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10229459/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Treatment-emergent adverse events in healthy participants

> “Dersimelagon was generally well tolerated in healthy participants, with the most common TEAEs being lentigo (52.8%) and skin hyperpigmentation (50.0%) after multiple doses.”
> “Overall, the incidence of TEAEs was relatively low, with most events occurring during Part A (SAD) and Part E (MAD) and the majority being mild to moderate in severity. No deaths or serious AEs were reported during any part of the study.”

Source: [Ogasawara et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10229459/)

Additional sources: [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: limitations of the first-in-human study

The study enrolled healthy participants rather than people with either disorder, so it does not describe clinical efficacy. Melanin density is a pharmacodynamic measure of target engagement and not a clinical outcome. The study was not designed to detect uncommon adverse events, and the transaminase elevations observed over 14 days of dosing were the basis for the intensified liver monitoring built into the later trials.

Source: [Ogasawara et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10229459/); [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)

## Related pages
- [Dersimelagon (MT-7117): Erythropoietic protoporphyria or X-linked protoporphyria](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Terms and abbreviations](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/terms-and-abbreviations.md)
- [Dersimelagon (MT-7117): Erythropoietic protoporphyria or X-linked protoporphyria](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/executive-summary.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Product information and disease description](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/product-information-and-disease-description.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Economic information and modeling report](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/economics) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/economics.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: References](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/references) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/references.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: prevalence by geography](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/prevalence) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/prevalence.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/cost-effectiveness-analyses.md)
